{"id":12383,"date":"2021-06-10T18:02:06","date_gmt":"2021-06-10T12:32:06","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12383"},"modified":"2022-08-16T09:57:48","modified_gmt":"2022-08-16T04:27:48","slug":"pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","title":{"rendered":"Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d293238b38a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d293238b38a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\/#Aelis_Farma_pockets_USD_30_Million_upfront_in_cannabis_use_disorder_deal_with_Indivior\" >Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\/#Alcyone_unveils_with_USD_23_Million_for_AAV_gene_therapies_for_Central_Nervous_System_disorders\" >Alcyone unveils with USD 23 Million for AAV gene therapies for Central Nervous System disorders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\/#Progentec_and_GSK_collaborate_to_study_lupus_management_tool\" >Progentec and GSK collaborate to study lupus management tool<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\/#Kozin_bags_USD_60_Million_to_exploit_the_weaknesses_of_drug-resistant_cancer\" >Kozin bags USD 60 Million to exploit the weaknesses of drug-resistant cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-aelis-farma-pockets-usd-30-million-upfront-in-cannabis-use-disorder-deal-with-indivior\"><span class=\"ez-toc-section\" id=\"Aelis_Farma_pockets_USD_30_Million_upfront_in_cannabis_use_disorder_deal_with_Indivior\"><\/span><strong>Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement.<\/p>\n\n\n\n<p>Aelis, clinical-stage French biotech zeroed in on brain disorders, will receive an upfront payment of USD 30 million from addiction-focused pharmaceutical company Indivior in a combined effort on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market\">cannabis use disorders<\/a><\/strong> such as cannabis-induced psychosis.<\/p>\n\n\n\n<p>Indivior is betting on the cannabis growth industry as it looks to cash in on the seven-year development of Aelis\u2019 lead candidate, AEF0117. The drug is a synthetic signalling-specific inhibitor, which prohibits the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cannabinoid-agonist-pipeline-insight\">cannabinoid type 1 receptor<\/a><\/strong>. Early and mid-stage testing of AEF0117 has hinted it is safe and tolerable and could be effective against the disorder as per the companies.<\/p>\n\n\n\n<p>If Aelis successfully finishes a scheduled phase 2b study, coordinated at Columbia University, the biotech could get a nice paycheck from Indivior for USD 100 million-plus potential milestone payments and royalties.&nbsp;<\/p>\n\n\n\n<p>In return, Indivior grabs an exclusive global option for AEF0117, including international rights on a patent covering the drug, as well as related compounds. Aelis\u2019 second compound, AEF0217, is the treatment of a cognitive disorder at the clinical stage. Additional compounds are being explored using Aelis\u2019 <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cannabinoid-receptor-cb1-inverse-agonists-pipeline-insight\">CB1-targeted drug<\/a><\/strong> screening platform.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-alcyone-unveils-with-usd-23-million-for-aav-gene-therapies-for-central-nervous-system-disorders\"><span class=\"ez-toc-section\" id=\"Alcyone_unveils_with_USD_23_Million_for_AAV_gene_therapies_for_Central_Nervous_System_disorders\"><\/span><strong>Alcyone unveils with USD 23 Million for AAV gene therapies for Central Nervous System disorders<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Massachusetts biotech unveiled itself USD 23 million in funding from RTW Investments with a pipeline of 12 <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\">adeno-associated viruses (AAV) gene therapy programs<\/a><\/strong> for severe Central Nervous System (CNS) disorders. Alcyone lead programs comprise ACTX-101, a <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/rett-syndrome-market\">Rett syndrome gene therapy<\/a><\/strong> in pre-IND enabling studies, and ACTX-401, IND-stage gene therapy for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-market\">spinal muscular atrophy <\/a><\/strong>with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\">respiratory distress type 1<\/a><\/strong>.<\/p>\n\n\n\n<p>Alcyone is coming out of the gates with four gene therapy platform technologies in deal with the Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital. The technologies comprise X-reactivation, conventional transgene replacement, vectorized exon skipping, and promotor modulation.<\/p>\n\n\n\n<p>The company also inked a broad strategic collaboration with Roche in December 2018, as per Alcyone. According to the company, the partnership is meant to optimize intrathecal therapies and create novel antisense oligonucleotide delivery treatment options for patients with neurological disorders.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Their mission at Alcyone Therapeutics is to offer life-changing therapies for children and their families affected by severe neurological conditions, said PJ Anand, CEO, president, and founder, in a statement.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Alcyone is going up against the latest biotechs to come with an aim on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-and-cell-therapies-targeting-cns-disorders-market\">CNS disorders<\/a><\/strong>. Taysha Gene Therapies is one of them. The Dallas-based pivotal-stage company offered preclinical data showing statistically major survival extension in mouse models of Rett syndrome.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-progentec-and-gsk-collaborate-to-study-lupus-management-tool\"><span class=\"ez-toc-section\" id=\"Progentec_and_GSK_collaborate_to_study_lupus_management_tool\"><\/span><strong>Progentec and GSK collaborate to study lupus management tool<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Progentec and GlaxoSmithKline (GSK) have entered an 18-month collaborative research deal to explore new measurement and management tools for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\">systemic lupus erythematosus (SLE or lupus)<\/a><\/strong>.<\/p>\n\n\n\n<p>Lupus is a complex autoimmune disease, which is difficult to detect and treat. Patient-generated data, such as data from wearable devices, is considered vital in chronic disease care as it facilitates continuous monitoring of relevant health signals in the clinic and outside of it.<\/p>\n\n\n\n<p>A developer of diagnostic and digital technologies, Progentec observed that these signals rise in predictive value on integration with <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence-in-healthcare\">artificial intelligence (AI) algorithms<\/a><\/strong> and lupus-specific laboratory tests.<\/p>\n\n\n\n<p>The latest research agreement will support two studies in the US to evaluate the use of available new clinical tools, comprising proteomics and digital health, in proffering a more practical approach to managing lupus.<\/p>\n\n\n\n<p>The first study will evaluate the impact of aisle MGMT on the process of clinical decision-making.<\/p>\n\n\n\n<p>A lupus management platform developed by Progentec, aisle MGMT includes the aisle DX Flare Risk Index test, the [AutoimmuneCorner] patient app, a smartwatch, and access to health coaching specific to the disease.<\/p>\n\n\n\n<p>The second study is based on the OASIS Study that started last year. Backed by Progentec\u2019s LupusCorner Research platform, the OASIS Study is a finished decentralized clinical study.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kozin-bags-usd-60-million-to-exploit-the-weaknesses-of-drug-resistant-cancer\"><span class=\"ez-toc-section\" id=\"Kozin_bags_USD_60_Million_to_exploit_the_weaknesses_of_drug-resistant_cancer\"><\/span><strong>Kozin bags USD 60 Million to exploit the weaknesses of drug-resistant cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Kojin Therapeutics raised USD 60 million to take advantage of iron-dependent cell death in drug-resistant cancer treatment. Series A rounds build biotechnology based on research done by its scientific founders at Harvard University and the Dana-Farber Cancer Institute.<\/p>\n\n\n\n<p>Massachusetts-based Kojin\u2019s big idea is to treat a disease by looking at the state of the cell. Traditionally, pharmaceutical researchers have defined cells by their location and appearance. For Kojin, the approach is shared by cells in several parts of the body and overlooks internal programs reflected in properties such as drug responsiveness. Kojin is ill by administering drugs to the state of the cells. They believe that they can selectively target their cells to address complex therapeutic challenges.<\/p>\n\n\n\n<p>The first focus is on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-cancer-hnc-market\">cancer treatment<\/a><\/strong> by targeting cells sensitive to iron-dependent cell death, also known as ferroptosis. Kozin aims to use small molecules to trigger a lipid peroxidation chain reaction that destroys the membranes of cells that are vulnerable to ferroptosis. Cellular status may also be applicable in the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cystic-fibrosis-market\">treatment of fibrosis<\/a><\/strong> and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-immune-deficiency-pid-epidemiology-forecast\">immune disorders<\/a><\/strong>.<\/p>\n\n\n\n<p>Polaris Partners, Newpath Partners, and Cathay Health have joined forces to raise Kojin to a USD 60 million Series A round, believing that the idea has potential. In Series A, Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, Dana-Farber\u2019s Binney Street Capital, and several family offices have joined the major investors.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders, will receive an upfront payment of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":12385,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16988,17042,17043,1663,16899,903,17045,349,420,639,17044,721],"industry":[17225],"therapeutic_areas":[17235,17237,17227,17228,17278],"class_list":["post-12383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aav-gene-therapies","tag-aelis-farma","tag-alcyone","tag-cannabis-use-disorder","tag-central-nervous-system-disorders","tag-gsk","tag-kozin","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-progentec","tag-systemic-lupus-erythematosus","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Kozin bags $60M | GSK&#039;s collaboration | Alcyone&#039;s AAV gene therapy<\/title>\n<meta name=\"description\" content=\"Progentec and GSK collaborate; Kozin bags $60M; Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kozin bags $60M | GSK&#039;s collaboration | Alcyone&#039;s AAV gene therapy\" \/>\n<meta property=\"og:description\" content=\"Progentec and GSK collaborate; Kozin bags $60M; Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-10T12:32:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:27:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kozin bags $60M | GSK's collaboration | Alcyone's AAV gene therapy","description":"Progentec and GSK collaborate; Kozin bags $60M; Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","og_locale":"en_US","og_type":"article","og_title":"Kozin bags $60M | GSK's collaboration | Alcyone's AAV gene therapy","og_description":"Progentec and GSK collaborate; Kozin bags $60M; Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-06-10T12:32:06+00:00","article_modified_time":"2022-08-16T04:27:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin","name":"Kozin bags $60M | GSK's collaboration | Alcyone's AAV gene therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin.jpg","datePublished":"2021-06-10T12:32:06+00:00","dateModified":"2022-08-16T04:27:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Progentec and GSK collaborate; Kozin bags $60M; Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-aelis-farma-alcyone-progentec-gsk-kozin#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin.jpg","width":772,"height":482,"caption":"latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/10175933\/latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AAV Gene therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aelis Farma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alcyone<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cannabis use disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Central nervous system disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kozin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Progentec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAV Gene therapies<\/span>","<span class=\"advgb-post-tax-term\">Aelis Farma<\/span>","<span class=\"advgb-post-tax-term\">Alcyone<\/span>","<span class=\"advgb-post-tax-term\">Cannabis use disorder<\/span>","<span class=\"advgb-post-tax-term\">Central nervous system disorders<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Kozin<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Progentec<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jun 10, 2021","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Jun 10, 2021 6:02 pm","modified":"Updated on Aug 16, 2022 9:57 am"},"featured_img_caption":"latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12383"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12383\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12385"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12383"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12383"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}